Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Brain Neoplasms × encorafenib × Clear all

Phase

Status

Recruiting 3 Active not recruiting 2 Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1 CNS 1

Conditions

Melanoma 6 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Skin Neoplasms 1 Pancreatic Neoplasms 1 Neurofibromatosis 1 1 Neoplasms 1 Neoplasm Metastasis 1 Lymphatic Metastasis 1 Lung Neoplasms 1 Hereditary Sensory and Autonomic Neuropathies 1 Hematologic Neoplasms 1 Gliosarcoma 1 Glioma 1 Glioblastoma 1 Brain Neoplasms 1 Astrocytoma 1

Interventions

Temozolomide 24 Radiotherapy 14 Radiosurgery 14 Bevacizumab 11 Magnetic Resonance Spectroscopy 7 Carboplatin 6 Topotecan 5 Radiation 5 Irinotecan 5 Capecitabine 5 Trastuzumab 4 Pemetrexed 4 Mental Status and Dementia Tests 4 Filgrastim 4 Erlotinib Hydrochloride 4 Aminolevulinic Acid 4 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 4 pembrolizumab 3 dabrafenib 3 cabozantinib 3 Sunitinib 3 Specimen Handling 3 Radiotherapy, Intensity-Modulated 3 Nivolumab 3 Granulocyte Colony-Stimulating Factor 3 Cyclophosphamide 3 trametinib 2 sargramostim 2 gadobutrol 2 fluoromisonidazole 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03911869 2023-05-31

POLARIS

Pfizer

Phase 2 Terminated

13 enrolled 55 charts

CNSDermatologic

Brain Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡